(2R,6R)-羟基去甲氯胺酮的靶点解卷积研究:一场难以捉摸的探索
该研究对氯胺酮代谢物(2R,6R)-HNK进行药理学表征和靶点解卷积,发现其不与任何已知或提出的氯胺酮靶点直接结合,在数千种人类蛋白中未发现其他直接相互作用,生物分布显示非选择性脑区富集且除肝脏外无特异性结合,在条件性位置偏爱、开阔场运动活性和静脉自我给药中无活性,但在强迫游泳试验中减少不动时间并引起小但显著的脑区代谢活动增加,该代谢特征与氯胺酮对映体不同。
要点
- (2R,6R)-HNK不直接结合任何已知或提出的氯胺酮靶点,在数千种人类蛋白中未发现其他直接相互作用。
- 生物分布显示非选择性脑区富集,除肝脏外无器官特异性结合;在物质使用障碍相关行为学程序中无活性。
- 在强迫游泳试验中减少不动时间,并引起小但显著的脑网络代谢活动增加,代谢特征与氯胺酮对映体不同。
核心结论
- (2R,6R)-HNK与氯胺酮及其对映体不共享药理学或行为学特征,但仍可能通过共同且先前未识别的机制发挥抗抑郁样疗效。
- 鉴于其药理学特征,预测(2R,6R)-HNK在临床试验中将表现出良好的安全性,其抗抑郁疗效需等待临床研究确定。
研究设计与样本
- 研究对(2R,6R)-HNK在已知氯胺酮靶点进行深入药理学表征,使用靶点解卷积方法在数千种人类蛋白中寻找新结合蛋白,并表征其生物分布及与物质使用障碍倾向相关的行为效应。
主要发现
- 与(S)-或(R)-氯胺酮不同,(2R,6R)-HNK不直接结合任何已知或提出的氯胺酮靶点。
- 在数千种人类蛋白的广泛筛选和靶点解卷积实验中,未发现其他直接的(2R,6R)-HNK-蛋白相互作用。
- 使用放射性标记的(2R,6R)-HNK进行生物分布研究,显示非选择性脑区富集,除肝脏外任何器官无特异性结合。
- (2R,6R)-HNK在条件性位置偏爱、开阔场运动活性和静脉自我给药程序中无活性。
- (2R,6R)-HNK在强迫游泳试验中减少不动时间,并引起脑区网络代谢活动小但显著的增加,该代谢特征与氯胺酮对映体诱导的脑代谢谱不同。
临床怎么用
- (2R,6R)-HNK在临床前模型中缺乏氯胺酮的解离和滥用特性,同时保留抗抑郁样行为疗效,可能成为替代候选。
- 预测(2R,6R)-HNK在临床试验中表现出良好的安全性,其抗抑郁疗效需等待临床研究确定。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The off-label use of racemic ketamine and the FDA approval of (S)-ketamine are promising developments for the treatment of depression. Nevertheless, racemic ketamine and (S)-ketamine are controlled substances with known abuse potential and their use is associated with undesirable side effects. For these reasons, research efforts have focused on identifying alternatives. One candidate is (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), a ketamine metabolite that in preclinical models lacks the dissociative and abuse properties of ketamine while retaining its antidepressant-like behavioral efficacy. (2R,6R)-HNK's mechanism of action however is unclear. The main goals of this study were to perform an in-depth pharmacological characterization of (2R,6R)-HNK at known ketamine targets, to use target deconvolution approaches to discover novel proteins that bind to (2R,6R)-HNK, and to characterize the biodistribution and behavioral effects of (2R,6R)-HNK across several procedures related to substance use disorder liability. We found that unlike (S)- or (R)-ketamine, (2R,6R)-HNK did not directly bind to any known or proposed ketamine targets. Extensive screening and target deconvolution experiments at thousands of human proteins did not identify any other direct (2R,6R)-HNK-protein interactions. Biodistribution studies using radiolabeled (2R,6R)-HNK revealed non-selective brain regional enrichment, and no specific binding in any organ other than the liver. (2R,6R)-HNK was inactive in conditioned place preference, open-field locomotor activity, and intravenous self-administration procedures. Despite these negative findings, (2R,6R)-HNK produced a reduction in immobility time in the forced swim test and a small but significant increase in metabolic activity across a network of brain regions, and this metabolic signature differed from the brain metabolic profile induced by ketamine enantiomers. In sum, our results indicate that (2R,6R)-HNK does not share pharmacological or behavioral profile similarities with ketamine or its enantiomers. However, it could still be possible that both ketamine and (2R,6R)-HNK exert antidepressant-like efficacy through a common and previously unidentified mechanism. Given its pharmacological profile, we predict that (2R,6R)-HNK will exhibit a favorable safety profile in clinical trials, and we must wait for clinical studies to determine its antidepressant efficacy.
引用
- Bonaventura J, Gomez JL, Carlton ML, et al. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Mol Psychiatry. 2022. PMID: 35768639. doi:10.1038/s41380-022-01673-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。